Analyst Ratings For Cytokinetics (NASDAQ:CYTK)
Today, Morgan Stanley raised its price target on Cytokinetics (NASDAQ:CYTK) to $18.00 per share.
Some recent analyst ratings include
- 2/20/2018-Cowen Reiterated Rating of Buy.
- 11/29/2017-Needham & Company LLC was Downgraded by analysts at Needham & Company LLC from a “Strong-Buy ” rating to a ” Buy” rating. They now have a $12.00 price target on the stock, up previously from $22.00 .
- 11/21/2017-JMP Securities Reiterated Rating of Outperform.
- 11/21/2017-Piper Jaffray Companies Reiterated Rating of Overweight.
Recent Insider Trading Activity For Cytokinetics (NASDAQ:CYTK)
Cytokinetics (NASDAQ:CYTK) has insider ownership of 7.20% and institutional ownership of 63.67%.
- On 1/16/2018 Caryn Gordon Mcdowell, Insider, sold 2,709 with an average share price of $9.00 per share and the total transaction amounting to $24,381.00.
- On 11/2/2017 Caryn Gordon Mcdowell, Insider, sold 4,260 with an average share price of $12.94 per share and the total transaction amounting to $55,124.40.
- On 11/1/2017 Fady Ibraham Malik, EVP, sold 7,321 with an average share price of $13.39 per share and the total transaction amounting to $98,028.19.
- On 11/1/2017 Robert I Blum, CEO, sold 5,000 with an average share price of $13.51 per share and the total transaction amounting to $67,550.00.
- On 10/6/2017 Caryn Gordon Mcdowell, Insider, sold 13,181 with an average share price of $15.49 per share and the total transaction amounting to $204,173.69.
- On 10/2/2017 Robert I Blum, CEO, sold 5,000 with an average share price of $14.59 per share and the total transaction amounting to $72,950.00.
- On 9/6/2017 Caryn Gordon Mcdowell, Insider, sold 10,131 with an average share price of $14.60 per share and the total transaction amounting to $147,912.60.
Recent Trading Activity for Cytokinetics (NASDAQ:CYTK)
Shares of Cytokinetics closed the previous trading session at 7.77 up +0.02 0.22% with shares trading hands.